BSE filing, NSE: HINDBIO. Summary written from the filing by ALFA Finder's alert engine.
Hindustan Bio Sciences Ltd: key numbers
- Share price
- ₹6.80
- Market cap
- ₹6.97 Cr
- Revenue (annual)
- ₹0.74 Cr
- Net profit (annual)
- ₹-0.08 Cr
- P/E (TTM)
- -33.8×Sector 46.5×
- Promoter holding
- 12.19%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Hindustan Bio Sciences Ltd
All →Hindustan Bio Sciences Board Meeting Date
Hindustan Bio Sciences Ltd intimated a board meeting on October 31, 2026 to consider unaudited financial results for the quarter ended September 30, 2026. The agenda items are proposed only; no results are yet approved.
Hindustan Bio Sciences Annual General Meeting
Hindustan Bio Sciences Ltd held its 34th Annual General Meeting on September 30, 2026. The meeting transacted business including adoption of financial statements and capital reduction.
Hindustan Bio Sciences Annual General Meeting
Hindustan Bio Sciences Limited has issued a notice for its 34th Annual General Meeting to be held on September 30, 2026, in Hyderabad.
Hindustan Bio Sciences Annual Report
Hindustan Bio Sciences Ltd submitted its 34th Annual Report for FY 2025-26, containing the AGM notice proposing a scheme of capital reduction.
Hindustan Bio Sciences Merger & Restructuring
Hindustan Bio Sciences Ltd announced a capital reduction scheme to set off accumulated losses against its share capital. No cash consideration is paid to shareholders.
Hindustan Bio Sciences Board Meeting Date
Hindustan Biosciences scheduled a board meeting for August 31, 2026, to discuss the 34th AGM notice and a proposed scheme of share capital reorganization.
Other other announcement announcements
All →eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.